[Considerations in the drug treatment of parkinsonism (author's transl)].
D000547:Amantadine / Q000627:therapeutic use; D001058:Apomorphine / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology; D004873:Ergolines / Q000627:therapeutic use; D005116:Extrapyramidal Tracts / Q000503:physiopathology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010726:Phosphodiesterase Inhibitors; D010891:Piribedil / Q000627:therapeutic use; D014202:Tremor / Q000517:prevention & control
D004873:Ergolines; D008996:Monoamine Oxidase Inhibitors; D018377:Neurotransmitter Agents; D010726:Phosphodiesterase Inhibitors; D001971:Bromocriptine; D007980:Levodopa; D000547:Amantadine; D010891:Piribedil; D001058:Apomorphine; D004298:Dopamine
Quoi de neuf dans le traitement du parkinson?